The cancer genome

Nature

Volumn 458, Issue 7239, 2009, Pages 719-724

  Stratton, Michael R ^a,b   Campbell, Peter J ^a,c   Futreal, P Andrew ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; K RAS PROTEIN; PROTEIN P53; TRASTUZUMAB;

CANCER; CYTOLOGY; DNA; GENOME;

ALLELE; CANCER CELL; CANCER GENETICS; CARCINOGENESIS; CHEMICAL MUTAGENESIS; DNA REPLICATION; DNA SEQUENCE; FUSION GENE; GENE AMPLIFICATION; GENE MUTATION; GENETIC LINKAGE; GENETIC VARIABILITY; GENOME; HUMAN; INDEL MUTATION; MISSENSE MUTATION; MITOSIS; ONCOGENE K RAS; PHENOTYPIC VARIATION; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; TUMOR GENE; TUMOR SUPPRESSOR GENE; GENETICS; GENOMICS; HUMAN GENOME; MUTATION; NEOPLASM; SEQUENCE ANALYSIS;

GENES, NEOPLASM; GENOME, HUMAN; GENOMICS; HUMANS; MUTATION; NEOPLASMS; SEQUENCE ANALYSIS;

EID: 64749094310     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature07943     Document Type: Review

References (59)

1. Garcia, M. et al. Global Cancer Facts and Figures 2007 (ACS, 2007).
2. von Hansemann, D. Ueber asymmetrische Zelltheilung in epithel Krebsen und deren biologische Bedeutung. Virchows Arch. Path. Anal. 119, 299 (1890).
3. Boveri, T. Zur Frage der Entstehung Maligner Tumoren. 1-64 (Gustav Fischer, 1914).
4. Avery, O. T., MacLeod, C. M.&McCarty, M. Studies on the chemical nature of the substance inducing transformation of Pneumococcal types: Induction of transformation by a desoxyribonucleic acid fraction isolated from Pneumoeoeeus type III. J. Exp. Med. 79, 137-158 (1944).
5. Watson, J. D. & Crick, F. H. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature 171, 737-738 (1953).
6. Loeb, L. A. & Harris, C. C. Advances in chemical carcinogenesis: a historical review and prospective. Cancer Res. 68, 6863-6872 (2008).
7. Nowell, P. & Hungerford, D. A minute chromosome in human granulocytic leukemia, Science 132, 1497 (1960).
8. Rowley, J. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290-293 (1973).
9. Krontiris, T. G. & Cooper, G. M. Transforming activity of human tumor DNAs. Proc. Natl Acad. Sci. USA 78, 1181-1184 (1981).
10. Shih, C., Padhy, L. C., Murray, M. & Weinberg, R. A. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 290, 261-264 (1981).
11. Reddy, E. P., Reynolds, R. K., Santos, E. & Barbacid, M. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene, Nature 300, 149-152 (1982).
12. Tabin, C. J. et al. Mechanism of activation of a human oncogene. Nature 300, 143-149 (1982).
13. Talbot, S. J. & Crawford, D. H. Viruses and tumours - an update, Eur. J. Cancer 40, 1998-2005 (2004).
14. Chatterjee, A., Mambo, E. & Sidransky, D. Mitochondrial DNA mutations in human cancer. Oncogene 25, 4663-4674 (2006).
15. Olivier, M., Hussain, S. P., Caron de Fromentel, C., Hainaut, P. & Harris, C. C. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer, IARC Sci. Publ. 247-270 (2004).
16. Kennedy, R. D. & D'Andrea, A. D. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes, J. Clin. Oncol. 24, 3799 - 3808 (2006).
17. Hanks, S. & Rahman, N. Aneuploidy-cancer predisposition syndromes: a new link between the mitotic spindle checkpoint and cancer. Cell Cycle 4, 225-227 (2005).
18. Bodmer, W. & Loeb, L. A. Genetic instability is not a requirement for tumor development. Cancer Res. 68, 3558-3561 (2008).
19. Loeb, L. A., Bielas, J. H., Beckman, R. A. & Bodmer, I. W. Cancers exhibit a mutator phenotype: clinical implications. Cancer Res. 68, 3551-3557 (2008).
20. .engauer, C., Kinzler, K. W. & Vogelstein, B. Genetic instabilities in human cancers,.Nature 396, 643-649 (1998).
21. Stewart, S. A. & Weinberg, R. A. Telomeres: cancer to human aging. Annu. Rev. Cell Dev. Biol. 22, 531-557 (2006).
22. Miller, D. G. On the nature of susceptibility to cancer. The presidential address. Cancer 46, 1307-1318 (1980).
23. Schinzel, A.C. & Hahn, W. C. Oncogenic transformation and experimental models of human cancer. Front. Biosci. 13, 71 - 84 (2008).
24. Beerenwinkel, N. et al. Genetic progression and the waiting time to cancer. PLoS Comput. Biol. 3, e225 (2007).
25. Roche-Lestienne, C. et al. Several types of mutations of the AbI gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100, 1014-1018 (2002).
26. Mullighan, C. G. et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322, 1377-1380 (2008).
27. Futreal, P. A. et al. A census of human cancer genes. Nature Rev. Cancer 4, 177-183 (2004).
28. Touw, I. P. & Erkeland, S. J. Retroviral insertion mutagenesis in mice as a comparative oncogenomics tool to identify disease genes in human leukemia, Mol. Ther. 15, 13-19 (2007).
29. Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005).
30. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer. Nature 448, 561-566 (2007).
31. Johnson, G. L. & Lapadat, R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases, Science 298, 1911-1912 (2002).
32. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
33. Haferiach, T. Molecular genetic pathways as therapeutic targets in acute myeloid leukemia, Hematology Am. Soc. Hematol. Educ. Prog. 2008, 400-411 (2008).
34. Druker, B. J. Translation of the Philadelphia chromosome into therapy for CML. Blood 112, 4808-4817 (2008).
35. Sleijfer, S., Wiemer, E. & Verweij, J. Drug insight: gastrointestinal stromal tumors (GIST)-the solid tumor model for cancer-specific treatment. Nature Clin. Prac. Oncol. 5, 102-111 (2008).
36. Mariani, G., Fasolo, A., De Benedict's, E. & Gianni, L. Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nature Clin. Prac. Oncol. 6, 93-104 (2009).
37. Bardelli, A. et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300, 949 (2003).
38. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008).
39. Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158 (2007).
40. Jones, S., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008).
41. Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008).
42. Sjoblom, T. et al. The consensus coding sequences of human breast and colorectal cancers, Science 314, 268-274 (2006).
43. Stephens, P. et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer, Nature Genet, 37, 590-592 (2005).
44. Wood, L. D. et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113 (2007).
45. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
46. Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).
47. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
48. Stephens, P. et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431, 525-526 (2004).
49. Levine, R. L. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387-397 (2005).
50. van Haften, G. et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nature Genet. (in the press).
51. Sawyers, C. Targeted cancer therapy. Nature 432, 294-297 (2004).
52. Hunter, C. et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after aikyiator chemotherapy. Cancer Res. 66, 3987-3991 (2006).
53. Cahill, D. P. et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin. Cancer Res. 13, 2038-2045 (2007).
54. Bignell, G. R. et al. Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution. Genome Res. 17, 1296-1303 (2007).
55. Volik, S. et al. End-sequence profiling: sequence-based analysis of aberrant genomes. Proc. Natl Acad. Sci. USA 100, 7696-7701 (2003).
56. Campbell, P. J. et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nature Genet. 40, 722-729 (2008).
57. Ley, T. J. et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456, 66-72 (2008).
58. Campbell, P. J. et al. Subclonal phylogenetic structures in cancer revea led by ultradeep sequencing. Proc. Natl Acad. Sci. USA 105, 13081-13086 (2008).
59. Thomas, R. K. et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nature Med. 12, 852-855 (2006).